New stock news | Macrogenics' Hong Kong IPO prospectus is invalidated.

10:27 14/01/2026

Hunan Meiji Biotechnology Co., Ltd. - B (referred to as Meiji Biotechnology), the Hong Kong IPO prospectus submitted on July 14, 2025, expired after 6 months on January 14, 2026, with CICC being its exclusive sponsor at the time of submission.

Hunan Magi Biotechnology Co., Ltd. -B (referred to as Magi Biotech) submitted its Hong Kong IPO prospectus on July 14, 2025, which expired on January 14, 2026 after 6 months, with Zhongjin as its exclusive sponsor at the time of submission. The prospectus shows that Magi Biotech is a biopharmaceutical company in the clinical stage, focusing on the discovery, development, and commercialization of innovative biologics to address unmet medical needs in allergic, autoimmune, inflammatory, and immunological diseases. Since its establishment in 2016, the company has independently researched and developed a strong pipeline consisting of eight innovative candidate products, including core product MG-K10, key products MG-014 and MG-013, and five other candidate products. All of these products are new-generation long-acting antibodies discovered and developed through the company's proprietary technology platform.

CABBEEN (02030) will distribute a final dividend of HK$0.0092 per share on May 8th.

CATHAY PAC AIR (00293) will distribute its second interim dividend of 0.64 Hong Kong dollars per share on May 7th.

FE HORIZON (03360) released its 2025 annual performance, with a net profit attributable to shareholders of 3.889 billion yuan, a year-on-year increase of 0.67%.

CABBEEN (02030) will distribute a final dividend of HK$0.0092 per share on May 8th.

CATHAY PAC AIR (00293) will distribute its second interim dividend of 0.64 Hong Kong dollars per share on May 7th.

FE HORIZON (03360) released its 2025 annual performance, with a net profit attributable to shareholders of 3.889 billion yuan, a year-on-year increase of 0.67%.